Topic: GlaxoSmithKline plc
Findings from a new study show, compared to placebo, treatment with high-dose prescription omega-3 fatty acids did not reduce the recurrence of symptomatic atrial fibrillation (AF) among patients with symptomatic paroxysmal AF or persistent AF who have no evidence of substantial structural ...
The troubled diabetes drug Avandia (rosiglitazone) stay available on the market with Restrictions In a very widely-anticipated ruling, a panel of experts decided not to advise that the FDA pull GlaxoSmithKline's blockbuster diabetes drug Avandia off of the market in the United ...
Fondaparinux appears to be safe and effective for reducing symptomatic superficial-vein thrombosis of the legs and may reduce the risk of that condition progressing to deep-vein thrombosis or pulmonary embolism, according to the results of a large randomized trial published in the ...
PK) Actos or Glaxo's (GSK) Avandia for diabetes face equal heart risks, according to a new study that contradicts earlier reports that suggested Actos was safer. " Earlier studies had found that patients taking Avandia faced a greater risk of heart attack ...
A majority of members of a key advisory committee recommended Wednesday that the US government allow diabetes drug Avandia to stay on the market with greater restrictions on its sale.Most of the panel's members agreed that the drug does increase the risk ...
Controversial diabetes drug Avandia does increase the risk of heart problems, a key panel of experts charged with deciding whether to pull the drug from the US markets said Wednesday.Nineteen of the 33 members on the panel convened by the Food and ...
The pharmacy company that makes Avandia knew more than a decade ago that the blockbuster diabetes drug caused an increased risk of heart problems but covered up the information, according to a report published Tuesday in The New York Times.. In a ...
LONDON/WASHINGTON (Reuters) - GlaxoSmithKline Plc's diabetes pill Avandia came under intense scrutiny on both sides of the Atlantic on Friday, leaving the drug's future uncertain as its maker battles a growing tide of lawsuits.In London, the European Medicines Agency (EMA)launched a new ...
WASHINGTON (Reuters) - An major trial of Avandia puts patients at risk and should be stopped, a U.S. advocacy group said on Tuesday in calling on regulators to halt the global study of the controversial GlaxoSmithKline Plc diabetes drug.The U.S. Food and ...
Patients who are hospitalized for heart failure are unlikely to have early follow-up after discharge, but those who are discharged from hospitals that have a higher rate of following up within one week have a lower risk of being readmitted within 30 ...
Photo Gallery
From Around the Web
Video Gallery
-
News Update: New Study Shows GlaxoSmithKline ...
A study in the Journal of the American Medical Association ...2010-06-28 -
GlaxoSmithKline up 1%; Pronova Biopharma Settles ...
GlaxoSmithKline plc (GSK) shares are up 0.89% to $38 ...2011-03-30 -
GlaxoSmithKline Plc (GSK)
Everyone is looking for a nice save haven in these ...2008-02-13
